Inpatient zoledronic acid in older hip fracture patients is well tolerated and safe

IF 4.3 3区 材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC
Frank Malgo, Floor J. A. van Deudekom, Roos Hup, Henk A. Formijne Jonkers, Diederik H. R. Kempen, Kerst de Vries, Hanna C. Willems, Annegreet G. Vlug
{"title":"Inpatient zoledronic acid in older hip fracture patients is well tolerated and safe","authors":"Frank Malgo,&nbsp;Floor J. A. van Deudekom,&nbsp;Roos Hup,&nbsp;Henk A. Formijne Jonkers,&nbsp;Diederik H. R. Kempen,&nbsp;Kerst de Vries,&nbsp;Hanna C. Willems,&nbsp;Annegreet G. Vlug","doi":"10.1007/s11657-024-01453-9","DOIUrl":null,"url":null,"abstract":"<div><h3>Summary</h3><p>Administering zoledronic acid (ZA) to older hip fracture patients during the hospital stay has faced safety concerns. However, in this study of 161 patients, no ZA-related side effects or readmissions were observed, demonstrating that ZA administration during hospitalization is safe and effective for secondary fracture prevention.</p><h3>Purpose</h3><p>According to the 2022 Dutch ‘Osteoporosis and fracture prevention’ guideline, zoledronic acid (ZA) is the preferred osteoporosis treatment for hip fracture patients. Less than 25% of hip fracture patients visit the outpatient fracture liaison service, therefore inpatient administration of ZA during the hip fracture hospitalization is now recommended in patients &gt; 75 years. In the OLVG Hospital, inpatient administration of ZA during hospitalization for hip fracture in older patients has been standard of care since 2020.</p><h3>Methods</h3><p>This single center retrospective observational follow-up study included hip fracture patients &gt; 75 years admitted to the orthogeriatric ward of the OLVG Hospital, and treated with 5 mg of ZA intravenously on the day of hospital discharge between June 2020 and December 2022. Life expectancy estimated &lt; 12 months, creatinine clearance &lt; 35 ml/min, hypocalcemia, and high risk of osteonecrosis of the jaw were contra-indications. During three months of follow-up (FU) adverse events, emergency room visits, hospital readmissions, and death were recorded.</p><h3>Results</h3><p>In 161 consecutive hospitalized hip fracture patients (mean age 86 ± 6 years, 65% female, 18% nursing home) ZA was administered and no adverse events were recorded. During 3 months of FU, 8 patients (5%) visited the emergency room, 19 patients (12%) were re-admitted to the hospital, 3 with a new fracture (2 contralateral hip, 1 radius), and 17 patients (11%) died of reasons unrelated to ZA.</p><h3>Conclusion</h3><p>This study shows that inpatient administration of zoledronic acid during hip fracture hospitalization is safe and feasible to prevent future fragility fractures in older hip fracture patients.</p></div>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s11657-024-01453-9","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0

Abstract

Summary

Administering zoledronic acid (ZA) to older hip fracture patients during the hospital stay has faced safety concerns. However, in this study of 161 patients, no ZA-related side effects or readmissions were observed, demonstrating that ZA administration during hospitalization is safe and effective for secondary fracture prevention.

Purpose

According to the 2022 Dutch ‘Osteoporosis and fracture prevention’ guideline, zoledronic acid (ZA) is the preferred osteoporosis treatment for hip fracture patients. Less than 25% of hip fracture patients visit the outpatient fracture liaison service, therefore inpatient administration of ZA during the hip fracture hospitalization is now recommended in patients > 75 years. In the OLVG Hospital, inpatient administration of ZA during hospitalization for hip fracture in older patients has been standard of care since 2020.

Methods

This single center retrospective observational follow-up study included hip fracture patients > 75 years admitted to the orthogeriatric ward of the OLVG Hospital, and treated with 5 mg of ZA intravenously on the day of hospital discharge between June 2020 and December 2022. Life expectancy estimated < 12 months, creatinine clearance < 35 ml/min, hypocalcemia, and high risk of osteonecrosis of the jaw were contra-indications. During three months of follow-up (FU) adverse events, emergency room visits, hospital readmissions, and death were recorded.

Results

In 161 consecutive hospitalized hip fracture patients (mean age 86 ± 6 years, 65% female, 18% nursing home) ZA was administered and no adverse events were recorded. During 3 months of FU, 8 patients (5%) visited the emergency room, 19 patients (12%) were re-admitted to the hospital, 3 with a new fracture (2 contralateral hip, 1 radius), and 17 patients (11%) died of reasons unrelated to ZA.

Conclusion

This study shows that inpatient administration of zoledronic acid during hip fracture hospitalization is safe and feasible to prevent future fragility fractures in older hip fracture patients.

老年髋部骨折患者对唑来膦酸的耐受性和安全性良好。
老年髋部骨折患者在住院期间服用唑来膦酸(ZA)的安全性一直备受关注。目的:根据 2022 年荷兰 "骨质疏松症和骨折预防 "指南,唑来膦酸 (ZA) 是髋部骨折患者首选的骨质疏松症治疗药物。只有不到 25% 的髋部骨折患者前往骨折联络门诊就诊,因此现在建议年龄大于 75 岁的髋部骨折患者在住院期间使用唑来膦酸。在 OLVG 医院,自 2020 年起,老年髋部骨折患者在住院期间服用ZA已成为标准治疗方法:这项单中心回顾性观察随访研究纳入了 2020 年 6 月至 2022 年 12 月期间在 OLVG 医院老年骨科病房住院治疗的髋部骨折患者(年龄大于 75 岁),他们在出院当天接受了 5 毫克 ZA 静脉注射治疗。预期寿命估计 结果:对 161 名连续住院的髋部骨折患者(平均年龄为 86 ± 6 岁,65% 为女性,18% 为疗养院患者)使用了ZA,没有不良反应记录。在 3 个月的治疗期间,8 名患者(5%)前往急诊室就诊,19 名患者(12%)再次入院,其中 3 名患者出现新的骨折(2 名患者为对侧髋部骨折,1 名患者为桡骨骨折),17 名患者(11%)因与ZA 无关的原因死亡:本研究表明,在髋部骨折住院期间使用唑来膦酸预防老年髋部骨折患者未来发生脆性骨折是安全可行的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.20
自引率
4.30%
发文量
567
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信